Kidswell BioKidswell Bio Corporation4584東証グロース医薬品FY ending Mar 2026, consolidated, J-GAAP
It lost about ¥2 for every ¥100 of sales at the operating level. Revenue changed +29.7% from the prior year, operating profit -596.8%.
Net margin × asset turnover = ROA; ROA × financial leverage = ROE
| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE |
|---|---|---|---|---|---|
| 2022 | — | —× | -15.4% | —× | — |
| 2023 | — | —× | -17.9% | —× | — |
| 2024 | — | —× | -31.7% | —× | — |
| 2025 | — | —× | -0.3% | —× | — |
| 2026 | — | —× | -6.3% | —× | — |
Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.
Annual trends in tangible-asset ratios and goodwill balance.
Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition
Track R&D investment and how long operating capital remains tied up before sales turn into cash.
R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 1,569 | 2,776 | 2,431 | 5,082 | 6,590 |
| Cost of revenue | 550 | 1,251 | 1,392 | 3,442 | 4,843 |
| Gross profit | 1,019 | 1,526 | 1,039 | 1,640 | 1,747 |
| SG&A | 1,670 | 2,077 | 2,375 | 1,612 | 1,886 |
| Operating income | -651 | -551 | -1,336 | 28 | -139 |
| Pretax income | -550 | -656 | -1,421 | 73 | -403 |
| Income tax | 1 | 1 | 2 | 94 | 11 |
| Net income attributable to owners | -535 | -657 | -1,422 | -21 | -414 |
| Operating margin | -41.5% | -19.8% | -54.9% | 0.5% | -2.1% |
Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.
Each bar totals 100% of assets; other is the residual.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Cash and equivalents | ¥1.16B | ¥1.07B | ¥2.23B | ¥3B | ¥3.29B |
| Total assets | ¥3.47B | ¥3.89B | ¥5.09B | ¥7.01B | ¥6.09B |
| Net assets | ¥1.7B | ¥1.23B | ¥831.5M | ¥1.41B | ¥1.65B |
| Share capital | ¥1.42B | ¥1.51B | ¥2.04B | ¥2.32B | ¥191.5M |
| Property, plant and equipment | ¥1.6M | ¥1.5M | ¥1.3M | ¥1.2M | ¥17.6M |
| Intangible assets excluding goodwill | ¥3.1M | ¥2.3M | ¥1.5M | ¥763K | ¥647K |
| Investment securities | ¥154.7M | ¥173.2M | ¥138.2M | ¥283.1M | ¥212.3M |
| Current assets | ¥3.29B | ¥3.7B | ¥4.92B | ¥6.7B | ¥5.84B |
| Current liabilities | ¥1.11B | ¥1.06B | ¥2.38B | ¥4.32B | ¥2.15B |
| Long-term borrowings | ¥525M | ¥1.07B | ¥1.34B | ¥680.9M | ¥2.06B |
| Total liabilities | ¥1.77B | ¥2.66B | ¥4.25B | ¥5.6B | ¥4.43B |
| Equity attributable to owners of parent | ¥1.52B | ¥1.04B | ¥669.9M | ¥1.21B | ¥1.52B |
| Retained earnings | -¥10.6B | -¥11.3B | -¥12.7B | -¥12.7B | -¥1.24B |
| Treasury stock | -¥73K | -¥73K | -¥73K | -¥73K | -¥73K |
EDINET (FSA Japan)
有価証券報告書－第26期(2025/04/01－2026/03/31)
EDINET (FSA Japan)
有価証券報告書－第25期(2024/04/01－2025/03/31)
EDINET (FSA Japan)
有価証券報告書－第24期(2023/04/01－2024/03/31)
EDINET (FSA Japan)
訂正有価証券報告書－第23期(2022/04/01－2023/03/31)
EDINET (FSA Japan)
有価証券報告書－第22期(令和3年4月1日－令和4年3月31日)
EDINET (FSA Japan)
有価証券報告書－第21期(令和2年4月1日－令和3年3月31日)
Extracted from XBRL: 44 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.